Diovan

Speaking to CNBC-TV18, Sarabjit Kaur Nangra of Angel Broking said on the bottomline, margins suffered due to forex loss. The drug maker reported a forex loss of Rs 132.6 crore versus gain of Rs 10.1 crore from a year ago period.

Sun's margins may reduce to 30-32% post merger: Surajit Pal

As 2014 comes to an end, Surajit Pal of Prabhudas Lilladher shares his outlook on the year that was and the possible trends for 2015.

Nifty to open with marginal gains ahead of FOMC meet today

US markets closed flat ahead of the FOMC meet that begins today. The Fed is expected to wrap up its third round of bond buying. Meanwhile, Asian markets trade cautious.

Here's why pharma sector will continue outperforming

Analysts at Motilal Oswal believe that Lupin, Ranbaxy, Cadila Healthcare, GSK Pharma, Torrent Pharma and Alembic Pharma will report stronger overall operational performance during this quarter.

Analysts advise how to trade Ranbaxy, say EBITDA may fall

Toansa is the fourth unit of the company which is banned and added to consent decree. With this, all of the company's India-based plants supplying to US are banned. Its Ohm Laboratories, the only plant which has USFDA approval, manufactures drugs using API from Toansa.

Ranbaxy likely to tie-up with MNC to source Diovan APIs

Diovan was the drug which was off-patented in September 2012 and Ranbaxy has a first-to-file (FTF) status over it. This means they will get six months of marketing exclusivity in the market.

Novartis raises 2013 sales and profit forecast for 2nd time

Novartis now expects yearly sales losses of USD 2.3 billion due to generic competition versus the earlier forecasts. Novartis had, in January 2013, forecasted to make losses of USD 3.5 billion and later in July quarter lowered it to USD 2.7 billion.

Impact of FDA import alert on Ranbaxy sentimental: Expert

If the companies' exclusivities which are still in the pipeline like Diovan and Valcyte are from this plant then there can be significant financial impact, says Sriram Rathi.

Ranbaxy rises after Nomura upgrades stock to 'buy'

Ranbaxy Laboratories shares gained 2 percent on Monday morning after Nomura Financial Advisory and Securities India upgraded the pharma major to "buy" from "neutral." The brokerage also raised its target price on the stock to Rs 475 from Rs 415.